Groundbreaking results from a phase III trial have set the stage for resmetirom to become the first drug approved for patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.
In the so-called MAESTRO-NASH study, NASH resolution with no worsening of fibrosis was achieved in 25.9% of patients who received the investigational drug at the 80-mg dose and 29.9% of those receiving the 100-mg dose, as compared with 9.7% of those in a placebo group (P
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/gastroenterology/generalhepatology/108629
